Edmond DE Rothschild Holding S.A. Sells 40,906 Shares of Boston Scientific Corporation $BSX

Key Points

• Edmond DE Rothschild Holding S.A. reduced its stake in Boston Scientific Corporation (BSX) by 27.5%, selling 40,906 shares and now holding 107,674 shares worth approximately $10.86 million.
• Several institutional investors have increased their positions in BSX, with Colonial Trust Co SC boosting its stake by 1,625% in the fourth quarter.
• Boston Scientific reported a 22.8% year-over-year revenue increase for the last quarter, reaching $5.06 billion and surpassing analysts' expectations.

Edmond DE Rothschild Holding S.A. decreased its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 27.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 107,674 shares of the medical equipment provider's stock after selling 40,906 shares during the period. Edmond DE Rothschild Holding S.A.'s holdings in Boston Scientific were worth $10,862,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of BSX. Brighton Jones LLC boosted its stake in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after buying an additional 226 shares in the last quarter. Bank Pictet & Cie Europe AG boosted its stake in Boston Scientific by 40.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after buying an additional 21,173 shares in the last quarter. Highview Capital Management LLC DE boosted its stake in Boston Scientific by 6.2% during the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after buying an additional 1,439 shares in the last quarter. Algert Global LLC acquired a new stake in Boston Scientific during the fourth quarter worth $297,000. Finally, Benjamin Edwards Inc. boosted its stake in shares of Boston Scientific by 5.9% in the 4th quarter. Benjamin Edwards Inc. now owns 14,983 shares of the medical equipment provider's stock valued at $1,338,000 after purchasing an additional 829 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Trading Up 0.9%

Shares of Boston Scientific stock traded up $0.92 during trading on Monday, hitting $108.14. 7,454,396 shares of the company were exchanged, compared to its average volume of 5,736,611. The firm has a market capitalization of $160.23 billion, a P/E ratio of 64.37, a price-to-earnings-growth ratio of 2.58 and a beta of 0.65. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $108.94. The firm's fifty day moving average price is $104.77 and its 200 day moving average price is $102.15. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the business's stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares in the company, valued at approximately $222,646.19. The trade was a 58.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company's stock, valued at $18,659,923.46. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock valued at $18,397,457 over the last 90 days. 0.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Leerink Partners initiated coverage on shares of Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 target price on the stock. Citigroup reiterated a "buy" rating and set a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Raymond James Financial raised their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research report on Thursday, July 24th. Needham & Company LLC restated a "buy" rating and issued a $115.00 price objective on shares of Boston Scientific in a research report on Wednesday, May 28th. Finally, Royal Bank Of Canada restated an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $117.79.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.